trimethyloxamine has been researched along with Atherogenesis in 141 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gut dysbiosis increases with aging, and it has been associated with the impairment of gut barrier function leading to the leakage of harmful metabolites such as trimethylamine (TMA)." | 9.41 | The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease. ( Al-Arawe, N; El Hage, R; Hinterseher, I, 2023) |
| " Among the well-known con¬tributors to atherosclerosis are less common ones, such as trimethylamine oxide (TMAO)." | 8.31 | TRIMETHYLAMINE OXIDE - FACTOR IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND A POTENTIAL TARGET FOR DIETARY AND PHARMACOLOGICAL INTERVENTIONS. ( Lazar, M; Olma, A; Streb, W, 2023) |
| "Trimethylamine-N-oxide (TMAO), a gut-microbiota-dependent metabolite after ingesting dietary choline, has been identified as a novel risk factor for atherosclerosis through inducing vascular inflammation." | 8.12 | Gut-Flora-Dependent Metabolite Trimethylamine-N-Oxide Promotes Atherosclerosis-Associated Inflammation Responses by Indirect ROS Stimulation and Signaling Involving AMPK and SIRT1. ( Hong, Y; Ji, N; Luo, X; Ma, W; Nie, Z; Shan, J; Xue, J; Zhang, T; Zhang, Y; Zhou, S; Zhu, W, 2022) |
| "Studies have shown that cadmium (Cd) exposure primarily occurs through diet, and Cd ingestion is a risk factor for atherosclerosis (AS)." | 8.12 | Curcumin attenuates cadmium-induced atherosclerosis by regulating trimethylamine-N-oxide synthesis and macrophage polarization through remodeling the gut microbiota. ( Chen, M; Ou, C; Zhang, J, 2022) |
| "Trimethylamine-N-oxide (TMAO), a derivative from the gut microbiota metabolite trimethylamine (TMA), has been identified to be an independent risk factor for promoting atherosclerosis." | 8.02 | Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. ( Du, Y; Hong, B; Jiang, J; Jiang, Z; Li, X; Su, C; Wang, L; Yang, M; Yang, Y; Zhang, J; Zhang, X; Zhang, Y, 2021) |
| "The aim of this study was to further investigate the relation between dietary choline and atherosclerosis in 2 atherogenic mouse models, the LDL receptor knockout (Ldlr-/-) and Apoe-/- mice." | 7.96 | Dietary Choline or Trimethylamine N-oxide Supplementation Does Not Influence Atherosclerosis Development in Ldlr-/- and Apoe-/- Male Mice. ( Aldana-Hernández, P; Curtis, JM; Field, CJ; Jacobs, RL; Leonard, KA; Zhao, YY, 2020) |
| "The aim of the present study was to assess whether L-carnitine supplementation may promote changes in selected serum biomarkers of atherosclerosis." | 7.91 | L-Carnitine Supplementation Increases Trimethylamine-N-Oxide but not Markers of Atherosclerosis in Healthy Aged Women. ( Grinberga, S; Hartmane, D; Lysiak-Szydlowska, W; Olek, RA; Pugovics, O; Samulak, JJ; Sawicka, AK, 2019) |
| " Choline supplementation did not increase atherosclerosis or plasma cholesterol in DKO mice." | 7.88 | Hepatic Expression of PEMT, but Not Dietary Choline Supplementation, Reverses the Protection against Atherosclerosis in Pemt-/-/Ldlr-/- Mice. ( Al Rajabi, A; Curtis, JM; Field, CJ; Jacobs, RL; Ju, T; Leonard, KA; Mi, S; Nelson, R; Thiesen, A; van der Veen, JN; Willing, BP; Zia, Y, 2018) |
| "Berberine (BBR) has long been used for treating bacterial diarrhea due to its antimicrobial effect and is currently used to treat obesity, diabetes, hyperlipemia and atherosclerosis." | 7.88 | Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. ( Geng, J; Hu, J; Hu, T; Jiang, Y; Li, J; Liu, S; Shi, Y; Wang, B; Yan, W, 2018) |
| "Recently, trimethylamine-N-oxide (TMAO) has been identified as a novel and independent risk factor for promoting atherosclerosis (AS) partially through inhibiting hepatic bile acid (BA) synthesis." | 7.83 | Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota. ( Chen, ML; Mi, MT; Ran, L; Yang, J; Yi, L; Zhang, QY; Zhang, Y; Zhou, X; Zhu, JD, 2016) |
| " We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice." | 7.79 | Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. ( Britt, EB; Brown, JM; Buffa, JA; Bushman, FD; Chen, J; DiDonato, JA; Fu, X; Hazen, SL; Koeth, RA; Krauss, RM; Levison, BS; Lewis, JD; Li, H; Li, L; Lusis, AJ; Org, E; Sheehy, BT; Smith, JD; Tang, WH; Wang, Z; Warrier, M; Wu, GD; Wu, Y, 2013) |
| "Circulating trimethylamine-N-oxide (TMAO) levels are strongly associated with atherosclerosis." | 7.79 | Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. ( Allayee, H; Bennett, BJ; Crooke, R; de Aguiar Vallim, TQ; Edwards, PA; Graham, M; Gregory, J; Hazen, SL; Lee, R; Lusis, AJ; Meng, Y; Shih, DM; Wang, Z, 2013) |
| "Atherosclerosis is a chronic inflammatory disease of the arterial wall involving inflammation, redox imbalance, and impaired cholesterol transport." | 5.72 | Chronic oral trimethylamine-N-oxide administration induces experimental incipient atherosclerosis in non-genetically modified mice. ( Ancuta, B; Cismaru, G; Decea, N; Filip, GA; Florea, CM; Moldovan, R; Rosu, R; Toma, V; Vlase, L, 2022) |
| " Trimethylamine N-oxide (TMAO) is produced from the metabolism of dietary choline and L-carnitine by intestinal microbiota, and many studies have shown that this important product inhibits cholesterol metabolism, induces platelet aggregation and thrombosis, and promotes atherosclerosis." | 5.41 | The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. ( Cai, XC; Han, HX; He, M; Kang, XX; Liu, X; Lv, EH; Tian, JQ; Wang, YT; Wen, PB; Xiao, L; Zhang, MY; Zhen, J; Zhou, Z, 2023) |
| " Gut dysbiosis increases with aging, and it has been associated with the impairment of gut barrier function leading to the leakage of harmful metabolites such as trimethylamine (TMA)." | 5.41 | The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease. ( Al-Arawe, N; El Hage, R; Hinterseher, I, 2023) |
| "l-Carnitine, an abundant nutrient in red meat, accelerates atherosclerosis in mice via gut microbiota-dependent formation of trimethylamine (TMA) and trimethylamine N-oxide (TMAO) via a multistep pathway involving an atherogenic intermediate, γ-butyrobetaine (γBB)." | 5.30 | l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. ( Bartlett, D; Cody, DB; Copeland, MF; Culley, MK; Dai, HJ; DiDonato, JA; Fu, X; Garcia-Garcia, JC; Gu, X; Hazen, SL; Kirsop, J; Koeth, RA; Lam-Galvez, BR; Levison, BS; Li, L; Li, XS; Tang, WHW; Wang, Z; Wu, Y, 2019) |
| " Articles were selected using the following search terms: "Intestinal microbiota", "trimethylamine N-oxide (TMAO)", "trimethylamine (TMA)", "cardiovascular", and "atherosclerosis"." | 4.91 | Intestinal Microbiota Metabolism and Atherosclerosis. ( Liu, TX; Niu, HT; Zhang, SY, 2015) |
| " Among the well-known con¬tributors to atherosclerosis are less common ones, such as trimethylamine oxide (TMAO)." | 4.31 | TRIMETHYLAMINE OXIDE - FACTOR IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND A POTENTIAL TARGET FOR DIETARY AND PHARMACOLOGICAL INTERVENTIONS. ( Lazar, M; Olma, A; Streb, W, 2023) |
| "Studies have shown that cadmium (Cd) exposure primarily occurs through diet, and Cd ingestion is a risk factor for atherosclerosis (AS)." | 4.12 | Curcumin attenuates cadmium-induced atherosclerosis by regulating trimethylamine-N-oxide synthesis and macrophage polarization through remodeling the gut microbiota. ( Chen, M; Ou, C; Zhang, J, 2022) |
| " Gut microbiota-dependent trimethylamine-N-oxide (TMAO) is associated with atherosclerosis, and geraniin, a natural polyphenol with various biological activities, might play key role in this process." | 4.12 | Anti-atherosclerotic effects of geraniin through the gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway in mice. ( Feng, Y; Li, H; Li, J; Lin, K; Liu, X; Tian, J; Wang, X; Xi, X; Yin, L; Yu, B; Zhao, P, 2022) |
| " Therefore, PSRC1 overexpression and reduced choline consumption may further alleviate atherosclerosis." | 4.12 | Deficiency of proline/serine-rich coiled-coil protein 1 (PSRC1) accelerates trimethylamine N-oxide-induced atherosclerosis in ApoE ( Chen, M; Chen, P; Guo, Z; Liu, D; Luo, T; Ou, C, 2022) |
| "Trimethylamine-N-oxide (TMAO), a gut-microbiota-dependent metabolite after ingesting dietary choline, has been identified as a novel risk factor for atherosclerosis through inducing vascular inflammation." | 4.12 | Gut-Flora-Dependent Metabolite Trimethylamine-N-Oxide Promotes Atherosclerosis-Associated Inflammation Responses by Indirect ROS Stimulation and Signaling Involving AMPK and SIRT1. ( Hong, Y; Ji, N; Luo, X; Ma, W; Nie, Z; Shan, J; Xue, J; Zhang, T; Zhang, Y; Zhou, S; Zhu, W, 2022) |
| " Trimethylamine-N-oxide (TMAO) and trimethylamine (TMA) are gut microbiota-derived metabolites, and both are known uraemic toxins that are implicated in CKD, atherosclerosis, colorectal cancer and cardiovascular risk." | 4.02 | Rapid Detection of Gut Microbial Metabolite Trimethylamine N-Oxide for Chronic Kidney Disease Prevention. ( Chang, YC; Chu, YH; Tain, YL; Wang, CC; Wang, CH; Yang, HW, 2021) |
| "Trimethylamine-N-oxide (TMAO), a gut-microbiota-dependent metabolite generated from its dietary precursors such as choline, has been identified as an independent risk factor for atherosclerosis." | 4.02 | Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality. ( Du, Y; Hong, B; Li, X; Su, C; Wang, L; Yang, Y; Zhang, X, 2021) |
| "Trimethylamine-N-oxide (TMAO), a derivative from the gut microbiota metabolite trimethylamine (TMA), has been identified to be an independent risk factor for promoting atherosclerosis." | 4.02 | Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. ( Du, Y; Hong, B; Jiang, J; Jiang, Z; Li, X; Su, C; Wang, L; Yang, M; Yang, Y; Zhang, J; Zhang, X; Zhang, Y, 2021) |
| "The aim of this study was to further investigate the relation between dietary choline and atherosclerosis in 2 atherogenic mouse models, the LDL receptor knockout (Ldlr-/-) and Apoe-/- mice." | 3.96 | Dietary Choline or Trimethylamine N-oxide Supplementation Does Not Influence Atherosclerosis Development in Ldlr-/- and Apoe-/- Male Mice. ( Aldana-Hernández, P; Curtis, JM; Field, CJ; Jacobs, RL; Leonard, KA; Zhao, YY, 2020) |
| "The aim of the present study was to assess whether L-carnitine supplementation may promote changes in selected serum biomarkers of atherosclerosis." | 3.91 | L-Carnitine Supplementation Increases Trimethylamine-N-Oxide but not Markers of Atherosclerosis in Healthy Aged Women. ( Grinberga, S; Hartmane, D; Lysiak-Szydlowska, W; Olek, RA; Pugovics, O; Samulak, JJ; Sawicka, AK, 2019) |
| "L-carnitine supplementation elevates plasma trimethylamine-N-oxide (TMAO), which may participate in atherosclerosis development by affecting cholesterol metabolism." | 3.91 | Plasma Trimethylamine-N-oxide following Cessation of L-carnitine Supplementation in Healthy Aged Women. ( Olek, RA; Samborowska, E; Samulak, JJ; Sawicka, AK, 2019) |
| " Furthermore, unlike chronic dietary choline, TML supplementation in mice failed to elevate plasma TMAO or heighten thrombosis potential in vivo." | 3.88 | Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. ( Allayee, H; Buffa, JA; Cajka, T; DiDonato, JA; Fiehn, O; Gu, X; Han, Y; Hartiala, JA; Hazen, SL; Hurd, AG; Kerby, RL; Li, L; Li, XS; Lüscher, TF; Nemet, I; Obeid, S; Rey, FE; Roberts, AB; Romano, KA; Shahen, CJ; Skye, SM; Tang, WHW; Wagner, MA; Wang, Z; Wu, Y, 2018) |
| "Berberine (BBR) has long been used for treating bacterial diarrhea due to its antimicrobial effect and is currently used to treat obesity, diabetes, hyperlipemia and atherosclerosis." | 3.88 | Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. ( Geng, J; Hu, J; Hu, T; Jiang, Y; Li, J; Liu, S; Shi, Y; Wang, B; Yan, W, 2018) |
| " Choline supplementation did not increase atherosclerosis or plasma cholesterol in DKO mice." | 3.88 | Hepatic Expression of PEMT, but Not Dietary Choline Supplementation, Reverses the Protection against Atherosclerosis in Pemt-/-/Ldlr-/- Mice. ( Al Rajabi, A; Curtis, JM; Field, CJ; Jacobs, RL; Ju, T; Leonard, KA; Mi, S; Nelson, R; Thiesen, A; van der Veen, JN; Willing, BP; Zia, Y, 2018) |
| "The choline-derived metabolite trimethylamine N-oxide (TMAO) has been demonstrated to contribute to atherosclerosis and is associated with coronary artery disease risk." | 3.83 | Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB. ( Hazen, SL; Lusis, AJ; Meng, Y; Qi, H; Seldin, MM; Shih, DM; Wang, Z; Zhu, W, 2016) |
| "Recently, trimethylamine-N-oxide (TMAO) has been identified as a novel and independent risk factor for promoting atherosclerosis (AS) partially through inhibiting hepatic bile acid (BA) synthesis." | 3.83 | Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota. ( Chen, ML; Mi, MT; Ran, L; Yang, J; Yi, L; Zhang, QY; Zhang, Y; Zhou, X; Zhu, JD, 2016) |
| "We performed silencing and overexpression studies of flavin containing monooxygenase (FMO) 3 in hyperlipidemic mouse models to examine its effects on trimethylamine N-oxide (TMAO) levels and atherosclerosis." | 3.81 | Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. ( Bennett, BJ; Brown, JM; Charugundla, S; Che, N; Graham, M; Hazen, SL; Lee, R; Lusis, AJ; Meng, Y; Pan, C; Qi, H; Shih, DM; Vallim, T; Wang, Z; Wu, J, 2015) |
| " Here we test the hypothesis that gut microbial transplantation can transmit choline diet-induced TMAO production and atherosclerosis susceptibility." | 3.81 | Transmission of atherosclerosis susceptibility with gut microbial transplantation. ( Bennett, BJ; Buffa, JA; DiDonato, JA; Gregory, JC; Hazen, SL; Levison, BS; Li, L; Lusis, AJ; Org, E; Wagner, MA; Wang, Z; Zhu, W, 2015) |
| "L-carnitine, a nutrient in red meat, was recently reported to accelerate atherosclerosis via a metaorganismal pathway involving gut microbial trimethylamine (TMA) formation and host hepatic conversion into trimethylamine-N-oxide (TMAO)." | 3.80 | γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. ( Buffa, JA; Culley, MK; DiDonato, JA; Gregory, JC; Hazen, SL; Koeth, RA; Levison, BS; Li, L; Lusis, AJ; Org, E; Smith, JD; Tang, WHW; Wang, Z; Wu, Y, 2014) |
| " We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice." | 3.79 | Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. ( Britt, EB; Brown, JM; Buffa, JA; Bushman, FD; Chen, J; DiDonato, JA; Fu, X; Hazen, SL; Koeth, RA; Krauss, RM; Levison, BS; Lewis, JD; Li, H; Li, L; Lusis, AJ; Org, E; Sheehy, BT; Smith, JD; Tang, WH; Wang, Z; Warrier, M; Wu, GD; Wu, Y, 2013) |
| "Circulating trimethylamine-N-oxide (TMAO) levels are strongly associated with atherosclerosis." | 3.79 | Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. ( Allayee, H; Bennett, BJ; Crooke, R; de Aguiar Vallim, TQ; Edwards, PA; Graham, M; Gregory, J; Hazen, SL; Lee, R; Lusis, AJ; Meng, Y; Shih, DM; Wang, Z, 2013) |
| "As we know, ischemic stroke is a heterogeneous disease with variable pathogenesis." | 2.82 | Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes. ( Cheng, A; Dai, L; Jing, J; Li, H; Meng, X; Song, B; Wang, A; Wang, Y; Xu, J; Xue, J; Zhao, M; Zheng, L, 2022) |
| "Inflammation is the key for the initiation and progression of atherosclerosis." | 2.66 | Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis. ( Chen, YH; Kao, HL; Liu, SF; Wu, MS; Wu, WK; Yang, KC; Yeh, CF, 2020) |
| "Phenylacetylglutamine, for example, was recently shown to promote adverse cardiovascular phenotypes in the host via interaction with multiple ARs (adrenergic receptors)-a class of key receptors that regulate cardiovascular homeostasis." | 2.66 | Gut Microbiota and Cardiovascular Disease. ( Hazen, SL; Weeks, TL; Witkowski, M, 2020) |
| "Atherosclerosis is a major cause of mortalities and morbidities worldwide." | 2.61 | Amelioration of TMAO through probiotics and its potential role in atherosclerosis. ( Din, AU; Gregersen, H; Hassan, A; Wang, G; Yin, T; Zhu, Y, 2019) |
| "Dysbiosis is associated with intestinal inflammation and reduced integrity of the gut barrier, which in turn increases circulating levels of bacterial structural components and microbial metabolites that may facilitate the development of CVD." | 2.58 | The gut microbiota as a novel regulator of cardiovascular function and disease. ( Battson, ML; Gentile, CL; Lee, DM; Weir, TL, 2018) |
| "Atherosclerosis is a progressive disease of large arteries and a leading cause of cardiovascular diseases and stroke." | 2.58 | Evolving targets for the treatment of atherosclerosis. ( Bhatt, LK; Johnston, TP; Solanki, A, 2018) |
| "Trimethylamine (TMA) is a tertiary amine with a characteristic fishy odour." | 2.53 | The complex metabolism of trimethylamine in humans: endogenous and exogenous sources. ( Bhargava, B; Chhibber-Goel, J; Gaur, A; Parakh, N; Sharma, A; Singhal, V, 2016) |
| "Atherosclerosis is considered a chronic inflammatory disease and an intervention targeting the inflammatory process could be a new therapeutic strategy for preventing atherosclerotic cardiovascular diseases (CVD)." | 2.52 | Intestinal Immunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic Cardiovascular Diseases. ( Emoto, T; Hirata, K; Kasahara, K; Kitano, N; Matsumoto, T; Mizoguchi, T; Sasaki, N; Yamashita, T, 2015) |
| "Inflammation is believed to play a key role by providing matrix-degrading metalloproteinases and also by inducing death of matrix-synthesizing smooth muscle cells." | 2.50 | Biomarkers of plaque instability. ( Shah, PK, 2014) |
| "This case-cohort study included Chronic Renal Insufficiency Cohort participants with baseline diabetes, estimated glomerular filtration rate <60 mL/min/1." | 1.91 | Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. ( Anderson, AH; Bhat, Z; Brown, J; Brunengraber, H; Charleston, J; Chen, J; Feldman, HI; He, J; Hostetter, TH; Hsu, CY; Ix, JH; Kimmel, PL; Mehta, R; Rao, P; Sapa, H; Schelling, JR; Schrauben, SJ; Seegmiller, JC; Shafi, T; Shlipak, MG; Townsend, R; Vasan, RS; Xie, D; Zhang, X, 2023) |
| "Atherosclerosis is a hallmark of cardiovascular disease, and lifestyle strongly impacts its onset and progression." | 1.72 | TMAO Upregulates Members of the miR-17/92 Cluster and Impacts Targets Associated with Atherosclerosis. ( Blanco, R; Daimiel, L; Dávalos, A; Díez-Ricote, L; Micó, V; Ordovás, JM; Ruiz-Valderrey, P; Tomé-Carneiro, J, 2022) |
| "Atherosclerosis is a chronic inflammatory disease of the arterial wall involving inflammation, redox imbalance, and impaired cholesterol transport." | 1.72 | Chronic oral trimethylamine-N-oxide administration induces experimental incipient atherosclerosis in non-genetically modified mice. ( Ancuta, B; Cismaru, G; Decea, N; Filip, GA; Florea, CM; Moldovan, R; Rosu, R; Toma, V; Vlase, L, 2022) |
| "Periodontitis is considered a risk factor for atherosclerosis, but the mechanism is not clear." | 1.62 | Experimental Periodontitis Deteriorated Atherosclerosis Associated With Trimethylamine N-Oxide Metabolism in Mice. ( Gao, Q; Hu, Q; Huang, L; Min, H; Song, S; Sun, W; Wang, Y; Xiao, L; Xie, S; Zhao, D; Zhou, X, 2021) |
| "The median TMAO levels in patients with STEMI and healthy controls were 2." | 1.51 | Relation of Circulating Trimethylamine N-Oxide With Coronary Atherosclerotic Burden in Patients With ST-segment Elevation Myocardial Infarction. ( Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Tan, Y; Yan, H; Zhao, H; Zhou, J; Zhou, P, 2019) |
| "Trimethylamine N-oxide was extensively formed in vivo in humanized-liver mice, but not in control mice." | 1.48 | Human plasma concentrations of trimethylamine N-oxide extrapolated using pharmacokinetic modeling based on metabolic profiles of deuterium-labeled trimethylamine in humanized-liver mice. ( Kusama, T; Miura, T; Mizuno, S; Shimizu, M; Suemizu, H; Uehara, S; Yamazaki, H, 2018) |
| "Atherosclerosis is a multifactorial and progressive disease commonly correlated with a high fat diet." | 1.40 | Serum metabonomic analysis of apoE(-/-) mice reveals progression axes for atherosclerosis based on NMR spectroscopy. ( Guo, J; Li, J; Li, X; Liu, Y; Wang, L; Wu, T; Yang, Y; Yuan, F; Zhang, Q; Zheng, L, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 76 (53.90) | 24.3611 |
| 2020's | 65 (46.10) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YC | 1 |
| Chu, YH | 1 |
| Wang, CC | 1 |
| Wang, CH | 1 |
| Tain, YL | 1 |
| Yang, HW | 1 |
| Xie, G | 1 |
| Yan, A | 1 |
| Lin, P | 1 |
| Wang, Y | 9 |
| Guo, L | 1 |
| Ringel, C | 1 |
| Dittrich, J | 1 |
| Gaudl, A | 1 |
| Schellong, P | 1 |
| Beuchel, CF | 1 |
| Baber, R | 1 |
| Beutner, F | 1 |
| Teren, A | 1 |
| Engel, C | 1 |
| Wirkner, K | 1 |
| Thiele, H | 1 |
| Büttner, P | 1 |
| Löffler, M | 1 |
| Scholz, M | 1 |
| Thiery, J | 1 |
| Ceglarek, U | 1 |
| Coué, M | 1 |
| Croyal, M | 1 |
| Habib, M | 1 |
| Castellano, B | 1 |
| Aguesse, A | 2 |
| Grit, I | 1 |
| Gourdel, M | 1 |
| Billard, H | 1 |
| Lépine, O | 1 |
| Michel, C | 1 |
| Ouguerram, K | 2 |
| Xu, J | 1 |
| Cheng, A | 1 |
| Song, B | 1 |
| Zhao, M | 2 |
| Xue, J | 3 |
| Wang, A | 1 |
| Dai, L | 1 |
| Jing, J | 1 |
| Meng, X | 1 |
| Li, H | 5 |
| Zheng, L | 6 |
| Liu, A | 1 |
| Zhang, Y | 4 |
| Xun, S | 1 |
| Sun, M | 1 |
| Wang, Z | 17 |
| Hazen, J | 1 |
| Jia, X | 2 |
| Org, E | 4 |
| Zhao, Y | 3 |
| Osborn, LJ | 1 |
| Nimer, N | 1 |
| Buffa, J | 1 |
| Culley, MK | 3 |
| Krajcik, D | 1 |
| van den Born, BH | 1 |
| Zwinderman, K | 1 |
| Levison, BS | 6 |
| Nieuwdorp, M | 2 |
| Lusis, AJ | 10 |
| DiDonato, JA | 9 |
| Hazen, SL | 19 |
| Panyod, S | 1 |
| Wu, WK | 2 |
| Chen, PC | 1 |
| Chong, KV | 1 |
| Yang, YT | 1 |
| Chuang, HL | 1 |
| Chen, CC | 1 |
| Chen, RA | 1 |
| Liu, PY | 1 |
| Chung, CH | 1 |
| Huang, HS | 1 |
| Lin, AY | 1 |
| Shen, TD | 1 |
| Yang, KC | 2 |
| Huang, TF | 1 |
| Hsu, CC | 1 |
| Ho, CT | 2 |
| Kao, HL | 2 |
| Orekhov, AN | 1 |
| Wu, MS | 2 |
| Sheen, LY | 1 |
| Xiao, L | 2 |
| Huang, L | 1 |
| Zhou, X | 3 |
| Zhao, D | 1 |
| Min, H | 1 |
| Song, S | 1 |
| Sun, W | 1 |
| Gao, Q | 1 |
| Hu, Q | 1 |
| Xie, S | 1 |
| Lin, K | 1 |
| Wang, X | 2 |
| Li, J | 6 |
| Zhao, P | 1 |
| Xi, X | 1 |
| Feng, Y | 1 |
| Yin, L | 2 |
| Tian, J | 1 |
| Liu, X | 2 |
| Yu, B | 1 |
| Luo, T | 1 |
| Liu, D | 1 |
| Guo, Z | 2 |
| Chen, P | 1 |
| Ou, C | 2 |
| Chen, M | 2 |
| Chen, CY | 1 |
| Leu, HB | 1 |
| Wang, SC | 1 |
| Tsai, SH | 1 |
| Chou, RH | 1 |
| Lu, YW | 1 |
| Tsai, YL | 1 |
| Kuo, CS | 1 |
| Huang, PH | 1 |
| Chen, JW | 1 |
| Lin, SJ | 1 |
| Zhou, P | 3 |
| Kang, JL | 1 |
| Cheng, QQ | 1 |
| Chen, MT | 1 |
| Xie, Y | 1 |
| Zhou, H | 1 |
| Ma, SR | 1 |
| Tong, Q | 1 |
| Lin, Y | 1 |
| Pan, LB | 1 |
| Fu, J | 1 |
| Peng, R | 1 |
| Zhang, XF | 1 |
| Zhao, ZX | 1 |
| Li, Y | 2 |
| Yu, JB | 1 |
| Cong, L | 1 |
| Han, P | 1 |
| Zhang, ZW | 1 |
| Yu, H | 2 |
| Jiang, JD | 1 |
| Xiong, X | 1 |
| Zhou, J | 3 |
| Fu, Q | 1 |
| Xu, X | 3 |
| Wei, S | 1 |
| Yang, S | 1 |
| Chen, B | 2 |
| Wang, M | 2 |
| Lee, Y | 1 |
| Lai, HTM | 1 |
| de Oliveira Otto, MC | 3 |
| Lemaitre, RN | 3 |
| Fretts, A | 2 |
| Sotoodehnia, N | 3 |
| Budoff, M | 3 |
| McKnight, B | 1 |
| Tang, WHW | 6 |
| Psaty, BM | 3 |
| Siscovick, DS | 3 |
| Mozaffarian, D | 3 |
| Zhou, S | 1 |
| Shan, J | 1 |
| Hong, Y | 1 |
| Zhu, W | 5 |
| Nie, Z | 1 |
| Ji, N | 1 |
| Luo, X | 1 |
| Zhang, T | 2 |
| Ma, W | 1 |
| Zhang, J | 2 |
| Zhu, B | 1 |
| Ren, H | 1 |
| Xie, F | 1 |
| An, Y | 1 |
| Tan, Y | 3 |
| Díez-Ricote, L | 1 |
| Ruiz-Valderrey, P | 1 |
| Micó, V | 1 |
| Blanco, R | 1 |
| Tomé-Carneiro, J | 1 |
| Dávalos, A | 1 |
| Ordovás, JM | 1 |
| Daimiel, L | 1 |
| Liu, C | 3 |
| Li, Z | 1 |
| Song, Z | 1 |
| Fan, X | 1 |
| Shao, H | 1 |
| Schönke, M | 1 |
| Boon, MR | 1 |
| Rensen, PCN | 1 |
| Cao, H | 3 |
| Zhu, Y | 5 |
| Hu, G | 3 |
| Zhang, Q | 4 |
| Melnychuk, I | 1 |
| Lizogub, VG | 1 |
| Canyelles, M | 1 |
| Borràs, C | 1 |
| Rotllan, N | 1 |
| Tondo, M | 1 |
| Escolà-Gil, JC | 1 |
| Blanco-Vaca, F | 1 |
| El Hage, R | 1 |
| Al-Arawe, N | 1 |
| Hinterseher, I | 1 |
| Zhen, J | 1 |
| Zhou, Z | 1 |
| He, M | 1 |
| Han, HX | 1 |
| Lv, EH | 1 |
| Wen, PB | 1 |
| Wang, YT | 1 |
| Cai, XC | 1 |
| Tian, JQ | 1 |
| Zhang, MY | 1 |
| Kang, XX | 1 |
| Li, XS | 3 |
| Nemet, I | 3 |
| Lüscher, TF | 2 |
| Florea, CM | 1 |
| Rosu, R | 1 |
| Cismaru, G | 1 |
| Moldovan, R | 1 |
| Vlase, L | 1 |
| Toma, V | 1 |
| Decea, N | 1 |
| Ancuta, B | 1 |
| Filip, GA | 1 |
| Olma, A | 1 |
| Streb, W | 1 |
| Lazar, M | 1 |
| Mu, HN | 1 |
| Zhao, XH | 1 |
| Zhang, RR | 1 |
| Li, ZY | 1 |
| Yang, RY | 1 |
| Wang, SM | 1 |
| Li, HX | 1 |
| Chen, WX | 1 |
| Dong, J | 1 |
| Schrauben, SJ | 1 |
| Sapa, H | 1 |
| Xie, D | 1 |
| Zhang, X | 6 |
| Anderson, AH | 1 |
| Shlipak, MG | 1 |
| Hsu, CY | 1 |
| Shafi, T | 1 |
| Mehta, R | 1 |
| Bhat, Z | 1 |
| Brown, J | 1 |
| Charleston, J | 1 |
| Chen, J | 6 |
| He, J | 1 |
| Ix, JH | 1 |
| Rao, P | 1 |
| Townsend, R | 1 |
| Kimmel, PL | 1 |
| Vasan, RS | 1 |
| Feldman, HI | 1 |
| Seegmiller, JC | 1 |
| Brunengraber, H | 1 |
| Hostetter, TH | 1 |
| Schelling, JR | 1 |
| Shi, G | 1 |
| Zeng, L | 1 |
| Shi, J | 1 |
| Chen, Y | 4 |
| Oktaviono, YH | 1 |
| Dyah Lamara, A | 1 |
| Saputra, PBT | 1 |
| Arnindita, JN | 1 |
| Pasahari, D | 1 |
| Saputra, ME | 1 |
| Suasti, NMA | 1 |
| Yang, Y | 5 |
| Karampoor, S | 1 |
| Mirzaei, R | 1 |
| Borozdkin, L | 1 |
| Zhu, P | 1 |
| Hemmati, M | 1 |
| Kashanipoor, S | 1 |
| Mazaheri, P | 1 |
| Alibabaei, F | 1 |
| Babaeizad, A | 1 |
| Asli, S | 1 |
| Mohammadi, S | 1 |
| Gorgin, AH | 1 |
| Ghods, K | 1 |
| Yousefi, B | 1 |
| Eslami, M | 1 |
| Jensen, PN | 1 |
| Fretts, AM | 1 |
| Sitlani, CM | 1 |
| Longstreth, WT | 1 |
| He, Z | 2 |
| Zhu, H | 2 |
| Liu, J | 3 |
| Kwek, E | 2 |
| Ma, KY | 2 |
| Chen, ZY | 2 |
| Mihuta, MS | 1 |
| Paul, C | 1 |
| Borlea, A | 1 |
| Roi, CM | 1 |
| Pescari, D | 1 |
| Velea-Barta, OA | 1 |
| Mozos, I | 1 |
| Stoian, D | 1 |
| Bi, SH | 1 |
| Su, C | 3 |
| Yang, P | 1 |
| Tang, W | 1 |
| Yang, W | 1 |
| He, L | 1 |
| Aldana-Hernández, P | 1 |
| Leonard, KA | 2 |
| Zhao, YY | 1 |
| Curtis, JM | 2 |
| Field, CJ | 2 |
| Jacobs, RL | 2 |
| Kuehn, BM | 1 |
| Hardin, SJ | 1 |
| Singh, M | 1 |
| Eyob, W | 1 |
| Molnar, JC | 1 |
| Homme, RP | 1 |
| George, AK | 1 |
| Tyagi, SC | 1 |
| Zysset-Burri, DC | 1 |
| Keller, I | 1 |
| Berger, LE | 1 |
| Neyer, PJ | 1 |
| Steuer, C | 1 |
| Wolf, S | 1 |
| Zinkernagel, MS | 1 |
| Din, AU | 1 |
| Hassan, A | 1 |
| Yin, T | 1 |
| Gregersen, H | 1 |
| Wang, G | 1 |
| Hao, W | 1 |
| Lei, L | 1 |
| Ho, HM | 1 |
| He, WS | 1 |
| Cardona, A | 1 |
| O'Brien, A | 1 |
| Bernier, MC | 1 |
| Somogyi, A | 1 |
| Wysocki, VH | 1 |
| Smart, S | 1 |
| He, X | 1 |
| Ambrosio, G | 1 |
| Hsueh, WA | 1 |
| Raman, SV | 1 |
| Montrucchio, C | 1 |
| De Nicolò, A | 1 |
| D'Ettorre, G | 1 |
| D'Ascenzo, F | 1 |
| Lazzaro, A | 1 |
| Tettoni, M | 1 |
| D'Avolio, A | 1 |
| Bonora, S | 1 |
| Celani, L | 1 |
| Di Perri, G | 1 |
| Calcagno, A | 1 |
| Wu, P | 1 |
| Tao, J | 1 |
| Wu, S | 1 |
| Xu, G | 2 |
| Wei, D | 1 |
| Yin, W | 1 |
| Lai, L | 1 |
| Lin, J | 1 |
| Zheng, J | 1 |
| Nie, X | 1 |
| Zhu, X | 1 |
| Liu, T | 1 |
| Li, Q | 1 |
| Jiang, H | 1 |
| Liu, Y | 3 |
| Dai, M | 1 |
| Koay, YC | 1 |
| Chen, YC | 1 |
| Wali, JA | 1 |
| Luk, AWS | 1 |
| Li, M | 1 |
| Doma, H | 1 |
| Reimark, R | 1 |
| Zaldivia, MTK | 1 |
| Habtom, HT | 1 |
| Franks, AE | 1 |
| Fusco-Allison, G | 1 |
| Yang, J | 2 |
| Holmes, A | 1 |
| Simpson, SJ | 1 |
| Peter, K | 1 |
| O'Sullivan, JF | 1 |
| Yu, ZL | 1 |
| Ding, L | 2 |
| Xue, CH | 1 |
| Zhang, TT | 1 |
| Wang, YM | 1 |
| Sheng, Z | 2 |
| Chen, R | 2 |
| Song, L | 2 |
| Zhao, H | 2 |
| Xu, B | 1 |
| Gao, R | 1 |
| Yan, H | 2 |
| Bin Waleed, K | 1 |
| Lu, Y | 1 |
| Liu, Q | 2 |
| Zeng, F | 1 |
| Tu, H | 2 |
| Wei, Y | 1 |
| Xu, S | 1 |
| Zhang, Z | 1 |
| Rongfeng, Y | 1 |
| Fan, A | 1 |
| Altaf, A | 2 |
| Chang, J | 1 |
| Wang, L | 4 |
| Witkowski, M | 1 |
| Weeks, TL | 1 |
| Verhaar, BJH | 1 |
| Prodan, A | 1 |
| Muller, M | 1 |
| Yeh, CF | 1 |
| Chen, YH | 1 |
| Liu, SF | 1 |
| Lv, Z | 1 |
| Shan, X | 1 |
| Tu, Q | 1 |
| Wang, J | 1 |
| Eshghjoo, S | 1 |
| Jayaraman, A | 1 |
| Sun, Y | 1 |
| Alaniz, RC | 1 |
| Duttaroy, AK | 1 |
| Iglesias-Carres, L | 1 |
| Hughes, MD | 1 |
| Steele, CN | 1 |
| Ponder, MA | 1 |
| Davy, KP | 1 |
| Neilson, AP | 1 |
| Waleed, KB | 1 |
| Tse, G | 1 |
| Lu, YK | 1 |
| Peng, CN | 1 |
| Ding, LG | 1 |
| Xia, YL | 1 |
| Wu, SL | 1 |
| Li, XT | 1 |
| Zhou, HQ | 1 |
| Chen, QY | 1 |
| Sun, AM | 1 |
| Chang, JL | 1 |
| Wang, LL | 1 |
| Li, X | 4 |
| Jiang, Z | 2 |
| Yang, M | 1 |
| Du, Y | 2 |
| Jiang, J | 1 |
| Hong, B | 2 |
| Xu, D | 1 |
| Zhao, W | 1 |
| Song, J | 1 |
| Wang, K | 1 |
| Wei, L | 1 |
| Xu, Y | 1 |
| Min, B | 1 |
| Tang, N | 1 |
| Jiang, X | 1 |
| Liu, H | 1 |
| Yan, S | 1 |
| Leng, H | 1 |
| Xue, Q | 1 |
| Peng, M | 1 |
| Wang, H | 1 |
| Liu, S | 2 |
| He, F | 1 |
| Zheng, T | 1 |
| Wan, S | 1 |
| Yang, F | 2 |
| Pei, X | 1 |
| Senthong, V | 1 |
| Kiatchoosakun, S | 1 |
| Wongvipaporn, C | 1 |
| Phetcharaburanin, J | 1 |
| Tatsanavivat, P | 1 |
| Sritara, P | 1 |
| Phrommintikul, A | 1 |
| Zheng, Y | 1 |
| He, JQ | 1 |
| Brown, JM | 5 |
| Mohammadi, A | 2 |
| Vahabzadeh, Z | 2 |
| Jamalzadeh, S | 1 |
| Khalili, T | 1 |
| Li, DY | 1 |
| Chen, ML | 2 |
| Zhu, XH | 1 |
| Ran, L | 2 |
| Lang, HD | 1 |
| Yi, L | 2 |
| Mi, MT | 2 |
| He, H | 1 |
| Lian, X | 1 |
| Tang, Z | 1 |
| Trenteseaux, C | 1 |
| Gaston, AT | 1 |
| Poupeau, G | 1 |
| de Coppet, P | 1 |
| Andriantsitohaina, R | 1 |
| Laschet, J | 1 |
| Amarger, V | 1 |
| Krempf, M | 1 |
| Nobecourt-Dupuy, E | 1 |
| Geng, J | 2 |
| Yang, C | 1 |
| Wang, B | 2 |
| Hu, T | 2 |
| Gu, Y | 1 |
| Yang, N | 1 |
| Gao, J | 2 |
| Cai, W | 1 |
| Ma, Y | 2 |
| Niu, X | 1 |
| Yang, G | 1 |
| Ascher, S | 1 |
| Reinhardt, C | 2 |
| Chung, RWS | 1 |
| Bursill, CA | 1 |
| Wu, BJ | 1 |
| Barter, PJ | 1 |
| Rye, KA | 1 |
| Solanki, A | 1 |
| Bhatt, LK | 1 |
| Johnston, TP | 1 |
| Battson, ML | 1 |
| Lee, DM | 1 |
| Weir, TL | 1 |
| Gentile, CL | 1 |
| Cajka, T | 1 |
| Buffa, JA | 4 |
| Hurd, AG | 1 |
| Gu, X | 2 |
| Skye, SM | 1 |
| Roberts, AB | 1 |
| Wu, Y | 5 |
| Li, L | 5 |
| Shahen, CJ | 1 |
| Wagner, MA | 2 |
| Hartiala, JA | 1 |
| Kerby, RL | 1 |
| Romano, KA | 1 |
| Han, Y | 1 |
| Obeid, S | 1 |
| Allayee, H | 4 |
| Rey, FE | 1 |
| Fiehn, O | 1 |
| Komaroff, AL | 1 |
| Shimizu, M | 1 |
| Suemizu, H | 1 |
| Mizuno, S | 1 |
| Kusama, T | 1 |
| Miura, T | 1 |
| Uehara, S | 1 |
| Yamazaki, H | 1 |
| Lindskog Jonsson, A | 1 |
| Caesar, R | 1 |
| Akrami, R | 1 |
| Fåk Hållenius, F | 1 |
| Borén, J | 1 |
| Bäckhed, F | 1 |
| Shan, Z | 1 |
| Clish, CB | 1 |
| Hua, S | 1 |
| Scott, JM | 1 |
| Hanna, DB | 1 |
| Burk, RD | 1 |
| Haberlen, SA | 1 |
| Shah, SJ | 1 |
| Margolick, JB | 1 |
| Sears, CL | 1 |
| Post, WS | 1 |
| Landay, AL | 1 |
| Lazar, JM | 1 |
| Hodis, HN | 1 |
| Anastos, K | 1 |
| Kaplan, RC | 1 |
| Qi, Q | 1 |
| Qiu, L | 1 |
| Tao, X | 1 |
| Xiong, H | 1 |
| Yu, J | 1 |
| Wei, H | 1 |
| Manor, O | 1 |
| Zubair, N | 1 |
| Conomos, MP | 1 |
| Rohwer, JE | 1 |
| Krafft, CE | 1 |
| Lovejoy, JC | 1 |
| Magis, AT | 1 |
| Shi, Y | 1 |
| Hu, J | 1 |
| Yan, W | 1 |
| Jiang, Y | 1 |
| Zia, Y | 1 |
| Al Rajabi, A | 1 |
| Mi, S | 1 |
| Ju, T | 1 |
| Nelson, R | 1 |
| Thiesen, A | 1 |
| Willing, BP | 1 |
| van der Veen, JN | 1 |
| Samulak, JJ | 2 |
| Sawicka, AK | 2 |
| Hartmane, D | 1 |
| Grinberga, S | 2 |
| Pugovics, O | 2 |
| Lysiak-Szydlowska, W | 1 |
| Olek, RA | 2 |
| Gautam, A | 1 |
| Paudel, YN | 1 |
| Abidin, S | 1 |
| Bhandari, U | 1 |
| Koeth, RA | 3 |
| Lam-Galvez, BR | 1 |
| Kirsop, J | 1 |
| Copeland, MF | 1 |
| Bartlett, D | 1 |
| Cody, DB | 1 |
| Dai, HJ | 1 |
| Fu, X | 3 |
| Garcia-Garcia, JC | 1 |
| Chang, M | 1 |
| Guo, Y | 1 |
| Zhang, L | 1 |
| Xue, C | 1 |
| Yanagita, T | 1 |
| Coffey, AR | 1 |
| Kanke, M | 1 |
| Smallwood, TL | 1 |
| Albright, J | 1 |
| Pitman, W | 1 |
| Gharaibeh, RZ | 1 |
| Hua, K | 1 |
| Gertz, E | 1 |
| Biddinger, SB | 1 |
| Temel, RE | 1 |
| Pomp, D | 1 |
| Sethupathy, P | 1 |
| Bennett, BJ | 7 |
| Joris, BR | 1 |
| Gloor, GB | 1 |
| Wilson, C | 1 |
| Knoll, D | 1 |
| de Hora, M | 1 |
| Kyle, C | 1 |
| Glamuzina, E | 1 |
| Webster, D | 1 |
| Cheng, X | 1 |
| Qiu, X | 1 |
| Yuan, C | 1 |
| Yang, X | 1 |
| Sinha, A | 1 |
| Scherzer, R | 1 |
| Rahalkar, S | 1 |
| Neilan, BD | 1 |
| Crane, H | 1 |
| Drozd, D | 1 |
| Martin, J | 1 |
| Deeks, SG | 1 |
| Hunt, P | 1 |
| Hsue, PY | 1 |
| Shih, DM | 4 |
| Schugar, RC | 1 |
| Meng, Y | 4 |
| Miikeda, A | 1 |
| Zieger, M | 1 |
| Lee, R | 3 |
| Graham, M | 3 |
| Cantor, RM | 1 |
| Mueller, C | 1 |
| Wu, X | 1 |
| Chen, L | 1 |
| Zeb, F | 1 |
| Huang, Y | 1 |
| An, J | 1 |
| Ren, J | 1 |
| Feng, Q | 1 |
| Samborowska, E | 1 |
| Weng, Z | 1 |
| Shao, W | 1 |
| Guo, W | 1 |
| Chen, C | 1 |
| Jiao, L | 1 |
| Wang, Q | 1 |
| Lu, Q | 1 |
| Sun, H | 1 |
| Gu, A | 1 |
| Hu, H | 1 |
| Chen, PY | 1 |
| Li, S | 1 |
| Koh, YC | 1 |
| Wu, JC | 1 |
| Yang, MJ | 1 |
| Pan, MH | 1 |
| Mantziaris, V | 1 |
| Kolios, G | 2 |
| Geng, WC | 1 |
| Zheng, Z | 1 |
| Guo, DS | 1 |
| Sheehy, BT | 1 |
| Britt, EB | 2 |
| Smith, JD | 3 |
| Wu, GD | 1 |
| Lewis, JD | 1 |
| Warrier, M | 1 |
| Krauss, RM | 1 |
| Tang, WH | 3 |
| Bushman, FD | 1 |
| Dambrova, M | 1 |
| Skapare-Makarova, E | 1 |
| Konrade, I | 1 |
| Tirzite, D | 1 |
| Petrovska, R | 1 |
| Kalvins, I | 1 |
| Liepins, E | 1 |
| Ussher, JR | 1 |
| Lopaschuk, GD | 1 |
| Arduini, A | 1 |
| Wu, T | 1 |
| Yuan, F | 1 |
| Guo, J | 1 |
| Shah, PK | 1 |
| Che, N | 1 |
| Charugundla, S | 1 |
| Qi, H | 3 |
| Wu, J | 2 |
| Pan, C | 2 |
| Vallim, T | 1 |
| Gregory, JC | 3 |
| Drosos, I | 1 |
| Tavridou, A | 1 |
| Yamashita, T | 1 |
| Kasahara, K | 1 |
| Emoto, T | 1 |
| Matsumoto, T | 1 |
| Mizoguchi, T | 1 |
| Kitano, N | 1 |
| Sasaki, N | 1 |
| Hirata, K | 1 |
| Najar, AG | 1 |
| Yaghoobi, MM | 1 |
| Jahani, Y | 1 |
| Liu, TX | 1 |
| Niu, HT | 1 |
| Zhang, SY | 1 |
| Yazdekhasti, N | 1 |
| Brandsch, C | 1 |
| Schmidt, N | 1 |
| Schloesser, A | 1 |
| Huebbe, P | 1 |
| Rimbach, G | 1 |
| Stangl, GI | 1 |
| Yamashina, A | 1 |
| Collins, HL | 1 |
| Drazul-Schrader, D | 1 |
| Sulpizio, AC | 1 |
| Koster, PD | 1 |
| Williamson, Y | 1 |
| Adelman, SJ | 1 |
| Owen, K | 1 |
| Sanli, T | 1 |
| Bellamine, A | 1 |
| Berge, RK | 2 |
| Ramsvik, MS | 1 |
| Bohov, P | 1 |
| Svardal, A | 2 |
| Nordrehaug, JE | 1 |
| Rostrup, E | 1 |
| Bruheim, I | 1 |
| Bjørndal, B | 1 |
| Davis, RC | 1 |
| Civelek, M | 1 |
| Orozco, L | 1 |
| Packard, RR | 1 |
| Eskin, E | 1 |
| Yan, M | 1 |
| Kirchgessner, T | 1 |
| Gargalovic, PS | 1 |
| Seldin, MM | 1 |
| Wilson, A | 1 |
| McLean, C | 1 |
| Kim, RB | 1 |
| Zhu, JD | 1 |
| Zhang, QY | 1 |
| Trøseid, M | 1 |
| Hov, JR | 1 |
| Nestvold, TK | 1 |
| Thoresen, H | 1 |
| Lappegård, KT | 1 |
| Wang, S | 1 |
| Xia, GH | 1 |
| He, Y | 1 |
| Liao, SX | 1 |
| Yin, J | 1 |
| Sheng, HF | 1 |
| Zhou, HW | 1 |
| Chhibber-Goel, J | 1 |
| Gaur, A | 1 |
| Singhal, V | 1 |
| Parakh, N | 1 |
| Bhargava, B | 1 |
| Sharma, A | 1 |
| Petriello, MC | 1 |
| Hoffman, JB | 1 |
| Sunkara, M | 1 |
| Wahlang, B | 1 |
| Perkins, JT | 1 |
| Morris, AJ | 1 |
| Hennig, B | 1 |
| Randrianarisoa, E | 1 |
| Lehn-Stefan, A | 1 |
| Hoene, M | 1 |
| Peter, A | 1 |
| Heinzmann, SS | 1 |
| Zhao, X | 1 |
| Königsrainer, I | 1 |
| Königsrainer, A | 1 |
| Balletshofer, B | 1 |
| Machann, J | 1 |
| Schick, F | 1 |
| Fritsche, A | 1 |
| Häring, HU | 1 |
| Lehmann, R | 1 |
| Stefan, N | 1 |
| Meyer, KA | 1 |
| Benton, TZ | 1 |
| Jacobs, DR | 1 |
| Lloyd-Jones, DM | 1 |
| Gross, MD | 1 |
| Carr, JJ | 1 |
| Gordon-Larsen, P | 1 |
| Zeisel, SH | 1 |
| Ma, G | 1 |
| Pan, B | 1 |
| Guo, C | 1 |
| Rak, K | 1 |
| Rader, DJ | 1 |
| Klipfell, E | 1 |
| Koeth, R | 1 |
| Dugar, B | 1 |
| Feldstein, AE | 1 |
| Chung, YM | 1 |
| Schauer, P | 1 |
| de Aguiar Vallim, TQ | 1 |
| Gregory, J | 1 |
| Crooke, R | 1 |
| Edwards, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Dietary Supplementation Allicor on Patients With Multifocal Atherosclerosis After Peripheral Artery Revascularization Treatment During a Year[NCT05813171] | Phase 4 | 300 participants (Anticipated) | Interventional | 2023-04-20 | Not yet recruiting | ||
| The Effects of Dietary Supplementation Allicor on the Effectiveness of Treatment of Patients After Coronary Arteria Revascularization[NCT05803759] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-04-10 | Recruiting | ||
| The Role of Gut Microbiota Metabolite, Trimethylamine N-oxide, in the Insulin Resistance Development[NCT05251207] | 60 participants (Anticipated) | Interventional | 2022-02-07 | Suspended (stopped due to PhD student responsible for the study has decided to terminate her education.) | |||
| CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease[NCT01731236] | Early Phase 1 | 100 participants (Anticipated) | Interventional | 2011-02-11 | Enrolling by invitation | ||
| "Plant-Based Meat vs Animal Red Meat: a Randomized Cross-over Trial"[NCT04510324] | 41 participants (Actual) | Interventional | 2020-11-01 | Completed | |||
| Impact of Facilitated Vegan Diet on Cardiometabolic Endpoints and Trimethylamine N-oxide[NCT05071196] | 70 participants (Anticipated) | Interventional | 2022-01-01 | Active, not recruiting | |||
| Impact of Diet and Gut Microbiota on Trimethylamine-N-oxide Production and Fate in Humans[NCT02558673] | 40 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)[NCT02016430] | 150 participants (Anticipated) | Interventional | 2014-04-04 | Recruiting | |||
| A Dietary Intervention With Functional Foods Reduce Metabolic Endotoxemia and Attenuates Biochemical Abnormalities in Subjects With Type 2 Diabetes by Modifying the Gut Microbiota.[NCT03421301] | 81 participants (Actual) | Interventional | 2014-08-07 | Completed | |||
| Effects of a Whole Food Based Nutritional Formulation on Trimethylamine N-oxide and Cardiometabolic Endpoints in Healthy Adults.[NCT05795946] | 45 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | |||
| Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS Patients[NCT04654689] | Phase 2 | 90 participants (Actual) | Interventional | 2021-11-20 | Completed | ||
| Low Fat Vegan Diet or American Heart Association Diet, Impact on Biomarkers of Inflammation, Oxidative Stress and Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol: A Four Week Randomized Trial[NCT01817491] | 60 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Effect of Choline Source and Gut Microbiota Composition on Trimethylamine-N-oxide Response in Humans[NCT04255368] | 44 participants (Actual) | Interventional | 2017-11-09 | Completed | |||
| Effects of Choline Supplementation on Fetal Growth in Gestational Diabetes Mellitus[NCT04302168] | 60 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | |||
| Analysis of MicroBial Metabolites After Eating Refined Food[NCT04308473] | 46 participants (Actual) | Interventional | 2020-09-01 | Active, not recruiting | |||
| Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans (EGGS)[NCT03039023] | 86 participants (Actual) | Interventional | 2016-09-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
PAQ self reported questions based on activity level from 1 (low activity) to 5 (high activity), overall PAQ score is a mean of the questions. (NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Reduced Fat Vegan Diet | 0.22 |
| American Heart Association Diet | -0.16 |
Body mass index z-scores, also called BMI standard deviation (s.d.) scores, are measures of relative weight adjusted for child age and sex. Given a child's age, sex, BMI, and an appropriate reference standard, a BMI z-score (or its equivalent BMI-for-age percentile) can be determined. Negative BMI z-scores indicate a BMI that is lower than the population mean, while positive BMI scores indicate a value that is higher than the population mean. A decrease in the BMI z-score over time indicate a lowering of the BMI. Z-scores of 1.03 and 1.64 correspond to the 85th and 95th percentiles of BMI-for-age, which are the definitions of overweight and obesity in children. (NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | Z Score (Mean) |
|---|---|
| Reduced Fat Vegan Diet | -0.14 |
| American Heart Association Diet | -0.03 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | Z score (Mean) |
|---|---|
| PB/AHA | -0.13 |
PAQ self reported questions based on activity level from 1 (low activity) to 5 (high activity), overall PAQ score is a mean of the questions. (NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| PB/AHA | 0.39 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mm Hg (Mean) | |||
|---|---|---|---|---|
| Children Systolic BP | Parents Systolic BP | Children Diastolic BP | Parent Diastolic BP | |
| American Heart Association Diet | -5.14 | -3.14 | -4.36 | -6.64 |
| Reduced Fat Vegan Diet | -6.43 | -7.96 | -2.61 | -3.46 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | -0.08 | -0.73 |
| Reduced Fat Vegan Diet | -1.12 | -1.29 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | cm (Mean) | |||
|---|---|---|---|---|
| Children Waist Circumference | Parents Waist Circumference | Children Midarm Circumference | Parents Midarm Circumference | |
| American Heart Association Diet | -2.96 | -0.49 | -1.14 | 0.35 |
| Reduced Fat Vegan Diet | -1.53 | -1.94 | -2.02 | -1.32 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -.64 | -5.43 |
| Reduced Fat Vegan Diet | 0.93 | 4.93 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | 0.21 | 0.14 |
| Reduced Fat Vegan Diet | 0.17 | -0.16 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/L (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | 2.78 | 0.21 |
| Reduced Fat Vegan Diet | -2.09 | -0.24 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -0.19 | -0.19 |
| Reduced Fat Vegan Diet | -0.17 | 0.16 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | uU/ml (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | 3.16 | -3.15 |
| Reduced Fat Vegan Diet | -5.42 | -3.11 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| total cholesterol children | triglycerides children | high-density lipoprotein cholesterol children | low-density lipoprotein cholesterol children | total cholesterol parents | triglycerides parents | high-density lipoprotein cholesterol parents | low-density lipoprotein cholesterol parents | |
| American Heart Association Diet | -16.50 | -13.14 | -2.93 | -11.00 | -7.14 | 16.86 | 16.86 | -5.50 |
| Reduced Fat Vegan Diet | -22.50 | -25.50 | -5.93 | -13.14 | -33.79 | 6.21 | -8.14 | -27.00 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | U/L (Mean) | |||
|---|---|---|---|---|
| alanine aminotransferase (ALT) children | aspartate aminotransferase (AST) children | alanine aminotransferase (ALT) parents | aspartate aminotransferase (AST) parents | |
| American Heart Association Diet | -1.14 | 0.00 | 4.57 | 4.43 |
| Reduced Fat Vegan Diet | 0.79 | 2.79 | 0.86 | 0.14 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | pmol/L (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -69.23 | 1.78 |
| Reduced Fat Vegan Diet | -75.34 | 16.91 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | -1.55 | -2.01 |
| Reduced Fat Vegan Diet | -3.05 | -3.64 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| Children adj mean ratio systolic BP | Children adj mean ratio diastolic BP | parents adj mean ratio systolic BP | parents adj mean ratio diastolic BP | |
| PB/AHA | 1.87 | 1.01 | 0.97 | 1.03 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | percentile (Mean) | |
|---|---|---|
| Children Change in BMI | Parents Change in BMI | |
| PB/AHA | -1.17 | -0.69 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | cm (Mean) | |||
|---|---|---|---|---|
| children waist circumference | parents waist circumference | children arm circumference | parents arm circumference | |
| PB/AHA | 1.32 | -1.14 | -1.25 | -1.68 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Children Weight | Parents Weight | |
| PB/AHA | -1.71 | -1.95 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| CHOL children | TRIG children | HDL children | LDL children | CHOL parents | TRIG parents | HDL parents | LDL parents | |
| PB/AHA | -10.34 | 1.01 | 0.17 | 0.95 | -27.29 | 0.95 | 0.94 | -21.92 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 1.01 | 1.06 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.99 | 0.96 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.46 | 0.68 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.26 | 1.14 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.7 | 0.87 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| ALT children | AST children | ALT parents | AST parents | |
| PB/AHA | 1 | 1.13 | 0.85 | 0.83 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.95 | 0.93 |
Changes in levels of non-labeled TMAO from baseline to Day 28 measured by established mass spectrometry techniques. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg in 24 hours (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 26.2 | 139.0 |
| Egg Whites + Choline Bitartrate Tablets | 29.3 | 186.9 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 27.5 | 221.8 |
| Phosphatidylcholine Capsules | 15.8 | 33.1 |
| Whole Hardboiled Eggs | 24.3 | 28.5 |
Changes in measured HDL levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 49 | 51 |
| Egg Whites + Choline Bitartrate Tablets | 48 | 50 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 57 | 56 |
| Phosphatidylcholine Capsules | 61 | 62 |
| Whole Hardboiled Eggs | 48 | 49 |
Changes in measured LDL levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 90 | 94 |
| Egg Whites + Choline Bitartrate Tablets | 104 | 101 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 108 | 118 |
| Phosphatidylcholine Capsules | 107 | 106 |
| Whole Hardboiled Eggs | 91 | 86 |
Changes in total cholesterol levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 180 | 172 |
| Egg Whites + Choline Bitartrate Tablets | 186 | 178 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 187 | 198 |
| Phosphatidylcholine Capsules | 175 | 172 |
| Whole Hardboiled Eggs | 156 | 158 |
Changes in measured triglyceride levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 106 | 96 |
| Egg Whites + Choline Bitartrate Tablets | 122 | 109 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 103 | 97 |
| Phosphatidylcholine Capsules | 74 | 84 |
| Whole Hardboiled Eggs | 86 | 100 |
Fasting plasma levels of betaine from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 38.2 | 69.0 |
| Egg Whites + Choline Bitartrate Tablets | 38.7 | 59.8 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 30.7 | 46.9 |
| Phosphatidylcholine Capsules | 33.6 | 46.3 |
| Whole Hardboiled Eggs | 28.1 | 39.7 |
Fasting plasma levels of carnitine from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 21.2 | 18.7 |
| Egg Whites + Choline Bitartrate Tablets | 21.1 | 18.9 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 21.5 | 15.6 |
| Phosphatidylcholine Capsules | 23.4 | 20.8 |
| Whole Hardboiled Eggs | 19.1 | 19.4 |
Fasting plasma levels of choline from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 7.5 | 12.9 |
| Egg Whites + Choline Bitartrate Tablets | 9.5 | 12.8 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 8.5 | 14.0 |
| Phosphatidylcholine Capsules | 7.6 | 10.6 |
| Whole Hardboiled Eggs | 8.3 | 10.9 |
Changes in levels of non-labeled TMAO from baseline to end-of-study (day 28) as measured by established techniques by mass spectrometry. (NCT03039023)
Timeframe: Baseline, 28 days
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 1.9 | 11.1 |
| Egg Whites + Choline Bitartrate Tablets | 2.6 | 28.1 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 2.3 | 12.3 |
| Phosphatidylcholine Capsules | 2.8 | 3.4 |
| Whole Hardboiled Eggs | 2.0 | 2.3 |
The activation and functioning of platelets within a single subject will be compared before and after increased choline intake. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | aggregation percentage (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 2.6 | 12.8 |
| Egg Whites + Choline Bitartrate Tablets | 3.0 | 29.4 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 2.3 | 12.3 |
| Phosphatidylcholine Capsules | 2.8 | 3.4 |
| Whole Hardboiled Eggs | 2.6 | 3.6 |
39 reviews available for trimethyloxamine and Atherogenesis
| Article | Year |
|---|---|
Trimethylamine N-oxide-a marker for atherosclerotic vascular disease.
Topics: Animals; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Humans; Methylamines | 2021 |
Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes.
Topics: Atherosclerosis; Humans; Ischemic Stroke; Methylamines; Risk Factors; Stroke | 2022 |
Therapeutic potential of traditional Chinese medicine against atherosclerosis: Targeting trimethylamine N-oxide.
Topics: Atherosclerosis; Humans; Lipid Metabolism; Medicine, Chinese Traditional; Methylamines | 2022 |
Trimethylamine N-Oxide Generated by the Gut Microbiota: Potential Atherosclerosis Treatment Strategies.
Topics: Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2022 |
Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease?
Topics: Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines; Prospec | 2023 |
The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease.
Topics: Aged; Aging; Animals; Atherosclerosis; Dysbiosis; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases.
Topics: Atherosclerosis; Cardiovascular Diseases; Choline; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
The roles of trimethylamine-N-oxide in atherosclerosis and its potential therapeutic aspect: A literature review.
Topics: Atherosclerosis; Choline; Endothelial Cells; Humans; Lyases; Oxides; Plaque, Atherosclerotic | 2023 |
The interplay between microbial metabolites and macrophages in cardiovascular diseases: A comprehensive review.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Humans; Macrophages; Methylamines | 2023 |
Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD).
Topics: Atherosclerosis; Cardiovascular Diseases; Dysbiosis; Gastrointestinal Microbiome; Humans; Inflammati | 2023 |
Diet-induced chronic syndrome, metabolically transformed trimethylamine-N-oxide, and the cardiovascular functions.
Topics: Animals; Atherosclerosis; Bacteria; Diet, High-Fat; Dysbiosis; Endothelium, Vascular; Gastrointestin | 2019 |
Amelioration of TMAO through probiotics and its potential role in atherosclerosis.
Topics: Animals; Atherosclerosis; Humans; Metabolomics; Methylamines; Mice; Microbiota; MicroRNAs; Probiotic | 2019 |
Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide.
Topics: Animals; Atherosclerosis; Gastrointestinal Microbiome; Humans; Methylamines; Risk Factors | 2020 |
Trimethylamine N-Oxide Generated by the Gut Microbiota Is Associated with Vascular Inflammation: New Insights into Atherosclerosis.
Topics: Atherosclerosis; Gastrointestinal Microbiome; Humans; Inflammation; Methylamines | 2020 |
Gut Microbiota and Cardiovascular Disease.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Cardiovascular Diseases; Carnitine; Choline; Disease | 2020 |
Gut Microbiota in Hypertension and Atherosclerosis: A Review.
Topics: Animals; Atherosclerosis; Blood Pressure; Fatty Acids, Volatile; Gastrointestinal Microbiome; Gram-N | 2020 |
Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis.
Topics: Animals; Atherosclerosis; Clinical Trials as Topic; Cytokines; Disease Progression; Dysbiosis; Fatty | 2020 |
Microbiota-Mediated Immune Regulation in Atherosclerosis.
Topics: Animals; Atherosclerosis; Basic Helix-Loop-Helix Transcription Factors; Foam Cells; Gastrointestinal | 2021 |
Role of Gut Microbiota and Their Metabolites on Atherosclerosis, Hypertension and Human Blood Platelet Function: A Review.
Topics: Animals; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Fatty Acids, Volatile; Gastroint | 2021 |
Use of dietary phytochemicals for inhibition of trimethylamine N-oxide formation.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Drug Discovery; Gastrointestinal Microbiome; Huma | 2021 |
Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery.
Topics: Animals; Atherosclerosis; Drug Discovery; Gastrointestinal Microbiome; Humans; Methylamines; Mice | 2017 |
Gut Microbiota and Atherosclerosis.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Carnitine; Diet; Disease Models, Animal; Gastrointes | 2017 |
The gut microbiota: An emerging risk factor for cardiovascular and cerebrovascular disease.
Topics: Animals; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Gastr | 2018 |
Evolving targets for the treatment of atherosclerosis.
Topics: ADAMTS Proteins; Animals; Atherosclerosis; Humans; Methylamines; PCSK9 Inhibitors; Proprotein Conver | 2018 |
The gut microbiota as a novel regulator of cardiovascular function and disease.
Topics: Aging; Animals; Anti-Bacterial Agents; Atherosclerosis; Bile Acids and Salts; Cardiovascular Disease | 2018 |
Unaccounted risk of cardiovascular disease: the role of the microbiome in lipid metabolism.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Carnitine; Choline; Energy Metabolism; Fatty Acids, | 2019 |
The decision to discontinue screening for carnitine uptake disorder in New Zealand.
Topics: Animals; Atherosclerosis; Biological Transport; Carnitine; Humans; Infant, Newborn; Methylamines; Ne | 2019 |
Gut Microbiota, Atherosclerosis, and Therapeutic Targets.
Topics: Atherosclerosis; Disease Management; Gastrointestinal Microbiome; Humans; Inflammation; Methylamines | 2019 |
Gut microbiota metabolism of L-carnitine and cardiovascular risk.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Diet; Dietary Supplements; Humans; Ins | 2013 |
Metaorganismal nutrient metabolism as a basis of cardiovascular disease.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Diet; Humans; Methylamines; Risk | 2014 |
The contributory role of gut microbiota in cardiovascular disease.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Choline; Diet; Female; Food; Humans; I | 2014 |
Biomarkers of plaque instability.
Topics: Antigens, Human Platelet; Apolipoprotein A-I; Atherosclerosis; Biomarkers; C-Reactive Protein; Coron | 2014 |
New aspects on the metabolic role of intestinal microbiota in the development of atherosclerosis.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Choline; Humans; Intestinal Mucosa; Intestines; Methyl | 2015 |
Intestinal Immunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic Cardiovascular Diseases.
Topics: Animals; Atherosclerosis; Bacteroidetes; Firmicutes; Gastrointestinal Microbiome; Humans; Immunity, | 2015 |
Intestinal Microbiota Metabolism and Atherosclerosis.
Topics: Atherosclerosis; Gastrointestinal Microbiome; Humans; Methylamines | 2015 |
[Gut Microbiota and Internal Diseases: Update Information. Topics: V. Gut Microbiota: Topics in Various Medical Fields; 1. Does intestinal flora promote atherosclerosis?].
Topics: Animals; Atherosclerosis; Diet; Gastrointestinal Tract; Genotype; Humans; Methylamines; Microbiota | 2015 |
Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Firmicutes; Gastrointestinal Microbiome; Humans; Met | 2016 |
The complex metabolism of trimethylamine in humans: endogenous and exogenous sources.
Topics: Air Pollutants; Animals; Atherosclerosis; Diet; Humans; Metabolism, Inborn Errors; Methylamines; Neo | 2016 |
7 trials available for trimethyloxamine and Atherogenesis
| Article | Year |
|---|---|
Plasma Trimethylamine-
Topics: Aged; Atherosclerosis; Female; Humans; Ischemic Stroke; Methylamines; Oxides; Prospective Studies; R | 2023 |
Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis.
Topics: Aged; Antihypertensive Agents; Atherosclerosis; Case-Control Studies; Diabetes Mellitus, Type 2; Dia | 2019 |
Association of trimethylamine N-oxide with coronary atherosclerotic burden in patients with non-ST-segment elevation myocardial infarction.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Coronary Artery Disea | 2020 |
l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Clostridiales; Female; Gastrointestinal Microbiome; Hu | 2019 |
l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Clostridiales; Female; Gastrointestinal Microbiome; Hu | 2019 |
l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Clostridiales; Female; Gastrointestinal Microbiome; Hu | 2019 |
l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Clostridiales; Female; Gastrointestinal Microbiome; Hu | 2019 |
Meldonium decreases the diet-increased plasma levels of trimethylamine N-oxide, a metabolite associated with atherosclerosis.
Topics: Adult; Atherosclerosis; Cardiovascular Agents; Carnitine; Diet; Female; HEK293 Cells; Humans; Male; | 2013 |
Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults - a pilot study.
Topics: Adolescent; Adult; Animals; Atherosclerosis; Betaine; Carnitine; Choline; Chylomicrons; Cytokines; D | 2015 |
Relationship of Serum Trimethylamine N-Oxide (TMAO) Levels with early Atherosclerosis in Humans.
Topics: Adiposity; Adult; Atherosclerosis; Female; Humans; Insulin Resistance; Intra-Abdominal Fat; Male; Me | 2016 |
95 other studies available for trimethyloxamine and Atherogenesis
| Article | Year |
|---|---|
Rapid Detection of Gut Microbial Metabolite Trimethylamine N-Oxide for Chronic Kidney Disease Prevention.
Topics: Atherosclerosis; Gastrointestinal Microbiome; Humans; Manganese Compounds; Methylamines; Oxides; Ren | 2021 |
Association of plasma trimethylamine N-oxide levels with atherosclerotic cardiovascular disease and factors of the metabolic syndrome.
Topics: Adult; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Humans; Metabolic Syndrome; Methylamine | 2021 |
Perinatal Administration of C-Phycocyanin Protects Against Atherosclerosis in apoE-Deficient Mice by Modulating Cholesterol and Trimethylamine-N-Oxide Metabolisms.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Disease Models, Animal; Female; Male; Meth | 2021 |
Trimethylamine N-oxide promotes atherosclerosis via regulating the enriched abundant transcript 1/miR-370-3p/signal transducer and activator of transcription 3/flavin-containing monooxygenase-3 axis.
Topics: Aged; Animals; Atherosclerosis; Case-Control Studies; Diet, High-Fat; Disease Models, Animal; Feedba | 2022 |
The Nutritional Supplement
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cecum; Cell Line; Dietary Supplements; Endothelial Cell | 2021 |
Atherosclerosis amelioration by allicin in raw garlic through gut microbiota and trimethylamine-N-oxide modulation.
Topics: Animals; Atherosclerosis; Disulfides; Garlic; Gastrointestinal Microbiome; Humans; Methylamines; Mic | 2022 |
Atherosclerosis amelioration by allicin in raw garlic through gut microbiota and trimethylamine-N-oxide modulation.
Topics: Animals; Atherosclerosis; Disulfides; Garlic; Gastrointestinal Microbiome; Humans; Methylamines; Mic | 2022 |
Atherosclerosis amelioration by allicin in raw garlic through gut microbiota and trimethylamine-N-oxide modulation.
Topics: Animals; Atherosclerosis; Disulfides; Garlic; Gastrointestinal Microbiome; Humans; Methylamines; Mic | 2022 |
Atherosclerosis amelioration by allicin in raw garlic through gut microbiota and trimethylamine-N-oxide modulation.
Topics: Animals; Atherosclerosis; Disulfides; Garlic; Gastrointestinal Microbiome; Humans; Methylamines; Mic | 2022 |
Experimental Periodontitis Deteriorated Atherosclerosis Associated With Trimethylamine N-Oxide Metabolism in Mice.
Topics: Animals; Atherosclerosis; Methylamines; Mice; Periodontitis; RNA, Ribosomal, 16S | 2021 |
Anti-atherosclerotic effects of geraniin through the gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway in mice.
Topics: Animals; Atherosclerosis; Gastrointestinal Microbiome; Glucosides; Hydrolyzable Tannins; Methylamine | 2022 |
Deficiency of proline/serine-rich coiled-coil protein 1 (PSRC1) accelerates trimethylamine N-oxide-induced atherosclerosis in ApoE
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, LDL; Choline; Inflammation; Leukocytes, Mononucl | 2022 |
Inhibition of Trimethylamine N-Oxide Attenuates Neointimal Formation Through Reduction of Inflammasome and Oxidative Stress in a Mouse Model of Carotid Artery Ligation.
Topics: Animals; Atherosclerosis; Carotid Arteries; Choline; Disease Models, Animal; Humans; Inflammasomes; | 2023 |
Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota.
Topics: Animals; Atherosclerosis; Choline; Cricetinae; Gastrointestinal Microbiome; Methylamines; Vitamins | 2022 |
The associations between TMAO-related metabolites and blood lipids and the potential impact of rosuvastatin therapy.
Topics: Atherosclerosis; Betaine; Carnitine; Cholesterol, LDL; Choline; Humans; Lipids; Methylamines; Rosuva | 2022 |
Dietary Meat, Trimethylamine N-Oxide-Related Metabolites, and Incident Cardiovascular Disease Among Older Adults: The Cardiovascular Health Study.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Humans; Meat; Methylamines; Risk Facto | 2022 |
Gut-Flora-Dependent Metabolite Trimethylamine-N-Oxide Promotes Atherosclerosis-Associated Inflammation Responses by Indirect ROS Stimulation and Signaling Involving AMPK and SIRT1.
Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Choline; Gastrointestinal Microbiome; Infla | 2022 |
Curcumin attenuates cadmium-induced atherosclerosis by regulating trimethylamine-N-oxide synthesis and macrophage polarization through remodeling the gut microbiota.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cadmium; Curcumin; Gastrointestinal Microbiome; Macroph | 2022 |
TMAO Upregulates Members of the miR-17/92 Cluster and Impacts Targets Associated with Atherosclerosis.
Topics: Animals; Atherosclerosis; Betaine; Cardiovascular Diseases; Carnitine; Choline; Humans; Inflammation | 2022 |
Choline and butyrate beneficially modulate the gut microbiome without affecting atherosclerosis in APOE*3-Leiden.CETP mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Butyrates; Cholesterol Ester Transfer Proteins; Choline | 2022 |
GUT MICROBIOTA COMPOSITION AND ITS METABOLITES CHANGES IN PATIENTS WITH ATHEROSCLEROSIS AND ATRIAL FIBRILLATION.
Topics: Atherosclerosis; Atrial Fibrillation; Bacteria; Gastrointestinal Microbiome; Humans | 2022 |
Trimethylamine N-oxide is associated with long-term mortality risk: the multi-ethnic study of atherosclerosis.
Topics: Adult; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Dementia; Humans; Methylamines; Neoplas | 2023 |
They eat what we eat, they digest what we ingest.
Topics: Atherosclerosis; Humans; Methylamines | 2023 |
Chronic oral trimethylamine-N-oxide administration induces experimental incipient atherosclerosis in non-genetically modified mice.
Topics: Animals; Atherosclerosis; C-Reactive Protein; Cholesterol; Inflammation; Male; Mice; Oxides; Rats; R | 2022 |
TRIMETHYLAMINE OXIDE - FACTOR IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND A POTENTIAL TARGET FOR DIETARY AND PHARMACOLOGICAL INTERVENTIONS.
Topics: Atherosclerosis; Carnitine; Choline; Humans; Methylamines | 2023 |
Choline and trimethylamine N-oxide supplementation in normal chow diet and western diet promotes the development of atherosclerosis in Apoe -/- mice through different mechanisms.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cardiovascular Diseases; Choline; Diet, Western; Dietar | 2023 |
Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
Topics: Arginine; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; D | 2023 |
Trimethylamine N-oxide Promotes Atherosclerosis by Regulating Low-Density Lipoprotein-Induced Autophagy in Vascular Smooth Muscle Cells Through PI3K/AKT/mTOR Pathway.
Topics: Atherosclerosis; Autophagy; Beclin-1; Humans; Lipoproteins, LDL; Muscle, Smooth, Vascular; Phosphati | 2023 |
Errata: Trimethylamine N-oxide Promotes Atherosclerosis by Regulating Low-Density Lipoprotein-Induced Autophagy in Vascular Smooth Muscle Cells Through PI3K/AKT/mTOR Pathway.
Topics: Atherosclerosis; Autophagy; Humans; Lipoproteins, LDL; Muscle, Smooth, Vascular; Phosphatidylinosito | 2023 |
Mangiferin alleviates trimethylamine-
Topics: Animals; Atherosclerosis; Cholesterol; Choline; Female; Gastrointestinal Microbiome; Methylamines; M | 2023 |
Connections between serum Trimethylamine N-Oxide (TMAO), a gut-derived metabolite, and vascular biomarkers evaluating arterial stiffness and subclinical atherosclerosis in children with obesity.
Topics: Acanthosis Nigricans; Adult; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; Child; Fem | 2023 |
Higher serum trimethylamine N-oxide (TMAO) levels are associated with increased visceral fat in hemodialysis patients.
Topics: Atherosclerosis; Humans; Intra-Abdominal Fat; Methylamines; Obesity; Renal Dialysis | 2023 |
Dietary Choline or Trimethylamine N-oxide Supplementation Does Not Influence Atherosclerosis Development in Ldlr-/- and Apoe-/- Male Mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Choline; Dietary Supplements; Male; Methylamines; Mice; | 2020 |
Gut Microbes Role in Heart Failure Explored.
Topics: Atherosclerosis; Bacteria; Butyrates; Diet; Dietary Fiber; Gastrointestinal Microbiome; Heart Failur | 2019 |
Retinal artery occlusion is associated with compositional and functional shifts in the gut microbiome and altered trimethylamine-N-oxide levels.
Topics: Actinobacteria; Aged; Atherosclerosis; Bacteroides; Bifidobacterium; Faecalibacterium; Female; Fluor | 2019 |
Fish Oil Is More Potent than Flaxseed Oil in Modulating Gut Microbiota and Reducing Trimethylamine-
Topics: Animals; Atherosclerosis; Bacteria; Fatty Acids, Volatile; Fish Oils; Gastrointestinal Microbiome; H | 2019 |
Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation.
Topics: Adult; Anti-Retroviral Agents; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Carotid Intima- | 2020 |
Trimethylamine N-oxide promotes apoE
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Human Umbilical Vein Endothelial Cells | 2020 |
Ranitidine and finasteride inhibit the synthesis and release of trimethylamine N-oxide and mitigates its cardiovascular and renal damage through modulating gut microbiota.
Topics: Animals; Atherosclerosis; Chromatography, High Pressure Liquid; Finasteride; Gastrointestinal Microb | 2020 |
Plasma levels of trimethylamine-N-oxide can be increased with 'healthy' and 'unhealthy' diets and do not correlate with the extent of atherosclerosis but with plaque instability.
Topics: Animal Feed; Animals; Atherosclerosis; Bacteria; Biomarkers; Carotid Artery Diseases; Choline; Coron | 2021 |
Dietary Trimethylamine
Topics: Animals; Atherosclerosis; Diet, High-Fat; Dietary Fats; Female; Humans; Male; Methylamines; Mice | 2020 |
Association Between Plasma Trimethylamine N-oxide and Neoatherosclerosis in Patients With Very Late Stent Thrombosis.
Topics: Atherosclerosis; Biomarkers; Coronary Vessels; Disease Progression; Drug-Eluting Stents; Female; Fol | 2020 |
Ginkgolide B treatment regulated intestinal flora to improve high-fat diet induced atherosclerosis in ApoE
Topics: Animals; Atherosclerosis; Bacteroides; Diet, High-Fat; Disease Models, Animal; Fibrinolytic Agents; | 2021 |
Trimethylamine N-oxide is associated with coronary atherosclerotic burden in non-ST-segment myocardial infarction patients: SZ-NSTEMI prospective cohort study.
Topics: Atherosclerosis; Humans; Methylamines; Non-ST Elevated Myocardial Infarction; Prospective Studies | 2021 |
Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome.
Topics: Animals; Atherosclerosis; Berberine; Choline; Diet; Disease Models, Animal; Disease Susceptibility; | 2021 |
The Relationship of Large-Artery Atherothrombotic Stroke with Plasma Trimethylamine N-Oxide Level and Blood Lipid-Related Indices: A Cross-Sectional Comparative Study.
Topics: Aged; Atherosclerosis; Biomarkers; Cross-Sectional Studies; Female; Humans; Lipids; Male; Methylamin | 2021 |
Ligustrum robustum Alleviates Atherosclerosis by Decreasing Serum TMAO, Modulating Gut Microbiota, and Decreasing Bile Acid and Cholesterol Absorption in Mice.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Cholesterol; Dietary Supplements; Female; Gastrointe | 2021 |
Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Cardiovascular Diseases; Case-Control Studies; Female; Gas | 2021 |
Pathogenic Mechanisms of Trimethylamine N-Oxide-induced Atherosclerosis and Cardiomyopathy.
Topics: Animals; Atherosclerosis; Betaine; Cardiomyopathies; Cardiovascular Diseases; Humans; Methylamines | 2022 |
Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality.
Topics: Akkermansia; Animals; Atherosclerosis; Bifidobacterium; Choline; Diabetes Mellitus, Type 2; Diet; Dy | 2021 |
Trimethylamine-N-oxide, as a risk factor for atherosclerosis, induces stress in J774A.1 murine macrophages.
Topics: Animals; Atherosclerosis; Cell Line; Cell Survival; HSP70 Heat-Shock Proteins; Macrophages; Membrane | 2018 |
Trimethylamine-N-Oxide Induces Vascular Inflammation by Activating the NLRP3 Inflammasome Through the SIRT3-SOD2-mtROS Signaling Pathway.
Topics: Animals; Antioxidants; Apoptosis Regulatory Proteins; Atherosclerosis; Cells, Cultured; Disease Mode | 2017 |
[Research progress of trimethylamine-N-oxide in the pathogenesis of atherosclerosis].
Topics: Atherosclerosis; Humans; Methylamines; Oxides | 2017 |
Perinatal Hypercholesterolemia Exacerbates Atherosclerosis Lesions in Offspring by Altering Metabolism of Trimethylamine-N-Oxide and Bile Acids.
Topics: Age Factors; Animals; Animals, Newborn; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; | 2017 |
Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway.
Topics: Animals; Apolipoproteins E; Atherosclerosis; CD36 Antigens; Cytokines; Disease Models, Animal; Disea | 2018 |
The Effect of Different l-Carnitine Administration Routes on the Development of Atherosclerosis in ApoE Knockout Mice.
Topics: Administration, Oral; Animals; Apolipoproteins E; Atherosclerosis; Carnitine; Diet, High-Fat; Humans | 2018 |
Effect of long-term dietary sphingomyelin supplementation on atherosclerosis in mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Dietary Supplements; Methylamines; Mice | 2017 |
Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk.
Topics: Aged; Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Cholesterol; Choline; Disease Mo | 2018 |
The Microbiome and Risk for Atherosclerosis.
Topics: Atherosclerosis; Gastrointestinal Absorption; Gastrointestinal Tract; Humans; Methylamines; Microbio | 2018 |
Human plasma concentrations of trimethylamine N-oxide extrapolated using pharmacokinetic modeling based on metabolic profiles of deuterium-labeled trimethylamine in humanized-liver mice.
Topics: Administration, Oral; Animals; Atherosclerosis; Deuterium; Hepatocytes; Humans; Methylamines; Mice; | 2018 |
Impact of Gut Microbiota and Diet on the Development of Atherosclerosis in Apoe
Topics: Animal Feed; Animals; Aortic Diseases; Atherosclerosis; Bacteria; Cholesterol; Choline; Diet, Wester | 2018 |
Gut Microbial-Related Choline Metabolite Trimethylamine-N-Oxide Is Associated With Progression of Carotid Artery Atherosclerosis in HIV Infection.
Topics: Atherosclerosis; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Choline; Female; Gastrointes | 2018 |
Lactobacillus plantarum ZDY04 exhibits a strain-specific property of lowering TMAO via the modulation of gut microbiota in mice.
Topics: Animals; Atherosclerosis; Bacteria; Choline; Female; Gastrointestinal Microbiome; Gastrointestinal T | 2018 |
A Multi-omic Association Study of Trimethylamine N-Oxide.
Topics: Atherosclerosis; Cardiovascular Diseases; Female; Gastrointestinal Microbiome; Humans; Male; Methyla | 2018 |
Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Berberine; Cytokines; Denaturing Gradient Gel Electroph | 2018 |
Hepatic Expression of PEMT, but Not Dietary Choline Supplementation, Reverses the Protection against Atherosclerosis in Pemt-/-/Ldlr-/- Mice.
Topics: Animals; Aorta; Atherosclerosis; Cholesterol; Cholesterol, Dietary; Choline; Diet, Western; Dietary | 2018 |
L-Carnitine Supplementation Increases Trimethylamine-N-Oxide but not Markers of Atherosclerosis in Healthy Aged Women.
Topics: Aged; Atherosclerosis; Biomarkers; Carnitine; Cholesterol; Dietary Supplements; Female; Humans; Meth | 2019 |
Guggulsterone, a farnesoid X receptor antagonist lowers plasma trimethylamine-
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; Cardiotonic Agents; Choline; Clost | 2019 |
Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Gene E | 2018 |
Relation of Circulating Trimethylamine N-Oxide With Coronary Atherosclerotic Burden in Patients With ST-segment Elevation Myocardial Infarction.
Topics: Atherosclerosis; Biomarkers; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female | 2019 |
microRNA-146a-5p association with the cardiometabolic disease risk factor TMAO.
Topics: Animals; Atherosclerosis; Chlorocebus aethiops; Choline; Cohort Studies; Collaborative Cross Mice; D | 2019 |
Trimethylamine N-oxide promotes tissue factor expression and activity in vascular endothelial cells: A new link between trimethylamine N-oxide and atherosclerotic thrombosis.
Topics: Aged; Atherosclerosis; Cells, Cultured; Endothelial Cells; Female; Humans; Male; Methylamines; Middl | 2019 |
Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV -Infected Adults.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atherosclerosis; Betaine; Carnitine; Carotid Artery Di | 2019 |
Genetic Deficiency of Flavin-Containing Monooxygenase 3 ( Fmo3) Protects Against Thrombosis but Has Only a Minor Effect on Plasma Lipid Levels-Brief Report.
Topics: Animals; Atherosclerosis; Choline; Disease Models, Animal; Lipid Metabolism; Methylamines; Mice; Mic | 2019 |
Regulation of circadian rhythms by NEAT1 mediated TMAO-induced endothelial proliferation: A protective role of asparagus extract.
Topics: ARNTL Transcription Factors; Asparagaceae; Atherosclerosis; Cell Division; Circadian Rhythm; CLOCK P | 2019 |
Plasma Trimethylamine-N-oxide following Cessation of L-carnitine Supplementation in Healthy Aged Women.
Topics: Aged; Atherosclerosis; Biomarkers; Carnitine; Dietary Supplements; Female; Follow-Up Studies; Health | 2019 |
FMO3 and its metabolite TMAO contribute to the formation of gallstones.
Topics: Animals; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Casse | 2019 |
Oolong Tea Extract and Citrus Peel Polymethoxyflavones Reduce Transformation of l-Carnitine to Trimethylamine-
Topics: Animals; Atherosclerosis; Bacteria; Biotransformation; Camellia sinensis; Carnitine; Citrus; Female; | 2019 |
Facile Fluorescence Monitoring of Gut Microbial Metabolite Trimethylamine
Topics: Atherosclerosis; Calixarenes; Fluorescence; Gastrointestinal Microbiome; Guanidine; Humans; Magnetic | 2019 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Topics: Animals; Atherosclerosis; Carnitine; Cholesterol; Choline; Desmosterol; Female; Humans; Intestines; | 2013 |
Serum metabonomic analysis of apoE(-/-) mice reveals progression axes for atherosclerosis based on NMR spectroscopy.
Topics: Animals; Atherosclerosis; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Choline; Diet, High-Fat; D | 2014 |
Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Cell Line, Tumor; Diet, Western; DNA-Binding Protein | 2015 |
γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Female; Gastrointestinal Tract; Methylamines; Mice; Mi | 2014 |
Transmission of atherosclerosis susceptibility with gut microbial transplantation.
Topics: Animals; Aorta; Atherosclerosis; Cecum; Choline; Diet; Disease Susceptibility; Female; Gastrointesti | 2015 |
Trimethylamine-N-Oxide Treatment Induces Changes in the ATP-Binding Cassette Transporter A1 and Scavenger Receptor A1 in Murine Macrophage J774A.1 cells.
Topics: Animals; Atherosclerosis; ATP Binding Cassette Transporter 1; Cell Line; Endoplasmic Reticulum Stres | 2016 |
Fish protein increases circulating levels of trimethylamine-N-oxide and accelerates aortic lesion formation in apoE null mice.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Fish Proteins; | 2016 |
L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE(-/-) transgenic mice expressing CETP.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Carnitine; Cells, Cultured; Cholesterol Ester Transfer | 2016 |
Genetic Architecture of Atherosclerosis in Mice: A Systems Genetics Analysis of Common Inbred Strains.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol | 2015 |
Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB.
Topics: Animals; Aorta; Aortitis; Atherosclerosis; Cell Adhesion; Cells, Cultured; Choline; Coculture Techni | 2016 |
Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota.
Topics: Animals; Atherosclerosis; Bacteria; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Female; G | 2016 |
Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery.
Topics: Adult; Atherosclerosis; Bariatric Surgery; Betaine; Body Mass Index; Cardiovascular Diseases; Carnit | 2016 |
[Distribution characteristics of trimethylamine N-oxide and its association with gut microbiota].
Topics: Adult; Atherosclerosis; Bacteria; Biomarkers; Cardiovascular Diseases; Chromatography, Liquid; Gastr | 2016 |
Dioxin-like pollutants increase hepatic flavin containing monooxygenase (FMO3) expression to promote synthesis of the pro-atherogenic nutrient biomarker trimethylamine N-oxide from dietary precursors.
Topics: Administration, Oral; Animals; Atherosclerosis; Biomarkers; Choline; Deuterium; Dietary Fats; Enviro | 2016 |
Microbiota-Dependent Metabolite Trimethylamine N-Oxide and Coronary Artery Calcium in the Coronary Artery Risk Development in Young Adults Study (CARDIA).
Topics: Adult; Atherosclerosis; Black or African American; Carotid Intima-Media Thickness; Coronary Artery D | 2016 |
Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion.
Topics: Atherosclerosis; Cell Adhesion; Cells, Cultured; Human Umbilical Vein Endothelial Cells; Humans; Met | 2017 |
Cardiovascular disease: the diet-microbe morbid union.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Choline; Diet; Dietary Fats; | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation.
Topics: Androgens; Animals; Atherosclerosis; Base Sequence; Bile Acids and Salts; Choline; Diet; Down-Regula | 2013 |